is high, and the optimal antithrombotic strategy for secondary prevention is unclear. We investigated whether congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or transient ischemic attack (TIA; CHADS 2 ) and CHA 2 DS 2 -VASc scores can stratify the long-term risk of ischemic stroke/TIA recurrence and death in ESUS. Methods-We pooled data sets of 11 stroke registries from Europe and America. ESUS was defined according to the Cryptogenic Stroke/ESUS International Working Group. Cox regression analyses were performed to investigate if prestroke CHADS 2 and congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category (CHA 2 DS 2 -VASc) scores were independently associated with the risk of ischemic stroke/TIA recurrence or death. The Kaplan-Meier product limit method was used to estimate the cumulative probability of ischemic stroke/TIA recurrence and death in different strata of the CHADS 2 and CHA 2 DS 2 -VASc scores. Results-One hundred fifty-nine (5.6% per year) ischemic stroke/TIA recurrences and 148 (5.2% per year) deaths occurred in 1095 patients (median age, 68 years) followed-up for a median of 31 months. Compared with CHADS 2 score 0, patients with CHADS 2 score 1 and CHADS 2 score >1 had higher risk of ischemic stroke/TIA recurrence (hazard ratio [HR], 2.38; 95% confidence interval [CI], 1.41-4.00 and HR, 2.72; 95% CI, 1.68-4.40, respectively) and death (HR, 3.58; 95% CI, and HR, 5.45; 95% CI, respectively). Compared with low-risk CHA 2 DS 2 -VASc score, patients with high-risk CHA 2 DS 2 -VASc score had higher risk of ischemic stroke/TIA recurrence (HR, 3.35; 95% CI,) and death (HR, 13.0; 95% CI, 
T he term Embolic Stroke of Undetermined Source (ESUS)
has been introduced by the Cryptogenic Stroke/ESUS International Working Group to include patients with ischemic stroke for whom the source of embolism remains unidentified despite recommended investigation; potential embolic sources include covert atrial fibrillation (AF), the mitral and aortic valves, the left cardiac chambers, the proximal cerebral arteries of the aortic arch, and the venous system via paradoxical embolism. 1, 2 The risk of stroke recurrence is higher in ESUS patients than in patients with noncardioembolic strokes, which could be a sign that current antithrombotic strategy of treating ESUS patients with antiplatelet agents may be suboptimal. 3, 4 In this context, 3 randomized trials are currently under way to assess whether antiplatelet or oral anticoagulation is the optimal treatment in ESUS patients. [5] [6] [7] The congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or transient ischemic attack (TIA) (CHADS 2 ) and congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category (CHA 2 DS 2 -VASc) scores are 2 wellvalidated tools, which are used to stratify the risk of stroke in patients with AF, and, by extension, they aid in the decision process on the antithrombotic treatment in AF patients. [8] [9] [10] [11] In addition, they are also associated with the risk of recurrence and death in patients with non-AF ischemic stroke. 12 In this context, we aimed to assess whether the CHADS 2 and CHA 2 DS 2 -VASc scores can stratify the long-term risk of ischemic stroke/TIA recurrence and death in ESUS patients.
Methods
The study population was derived from 11 stroke registries from Buenos Aires (Argentina), San José (Costa Rica), Helsinki (Finland), Athens and Larissa (Greece), Perugia and Savona (Italy), Mexico city (Mexico), and Barcelona and Madrid (Spain) ( Table I in the onlineonly Data Supplement). Prospectively collected data from all centers were pooled with the use of a standardized form with prespecified parameters and merged in the coordinating center (Larissa, Greece) where the pooled analysis was performed. The use of these registry data for research has been approved by the local ethics committees, where necessary.
ESUS was defined according to the criteria proposed by the Cryptogenic Stroke/ESUS International Working Group as a visualized nonlacunar brain infarct in the absence of the following: (1) extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis in arteries supplying the area of ischemia, (2) major-risk cardioembolic source, and (3) any other specific cause of stroke (eg, arteritis, dissection, migraine/vasospasm, and drug misuse). 1 Stroke severity was assessed with the National Institutes of Health Stroke Scale score at admission. 13 The CHADS 2 score was calculated taking into account the following parameters: congestive heart failure, hypertension, age 75 years or older, diabetes mellitus (1 point each), and previous stroke or TIA (2 points). 8, 9 The CHA 2 DS 2 -VASc score was calculated taking into account the following parameters: congestive heart failure, hypertension, age (1 point if 65-74 years; 2 points if ≥75 years), diabetes mellitus, previous stroke/TIA (2 points), vascular disease, and sex category (1 point if woman). 10 For the present analysis, the prestroke CHADS 2 and CHA 2 DS 2 -VASc scores were considered. The outcomes of interest were ischemic stroke/TIA recurrence and death.
Statistical Analysis
In all analyses, the CHADS 2 score was categorized and analyzed in 2 different ways: (1) CHADS 2 score 0 compared with CHADS 2 score 1 and CHADS 2 score >1; (2) CHADS 2 score ≤1 compared with CHADS 2 score >1. In similar, in all analyses, the CHA 2 DS 2 -VASc score was categorized and analyzed in 3 different ways: (1) 
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September 2016 stroke severity (evaluated by National Institutes of Health Stroke Scale score), smoking, hyperlipidemia, coronary artery disease (for CHADS 2 analysis only), peripheral artery disease (for CHADS 2 analysis only), acute treatment (no specific recanalization treatment, intravenous thrombolysis, pure acute endovascular, bridging, and other acute recanalization treatment), antithrombotic treatment at discharge (no treatment, antiplatelet[s], oral anticoagulant, and combination of antiplatelet with anticoagulant). The covariates that were significant in the univariate analyses were included in the multivariate Cox model. For the univariate analysis, the level of significance was set at 10% to reduce the risk of a type II error. For the multivariate analyses, the level of significance was set at 5%. Associations are presented as hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs). For both study outcomes, separate multivariate Cox regression analyses that included all variables of each score, regardless of the level of statistical significance at a univariate analysis, were performed, to identify the relative effect of each variable.
The Kaplan-Meier product limit method was used to estimate the cumulative probability of ischemic stroke/TIA recurrence and death in the aforementioned groups of the CHADS 2 and CHA 2 DS 2 -VASc scores. For patients lost during follow-up, survival data were censored at the last time known to be alive. Patients who experienced >1 recurrences during the follow-up period were censored at the time of the first event. Differences in Kaplan-Meier curves were evaluated with the Log-rank test, and the level of significance was set at 5%. Statistical analyses were performed with the Statistical Package for Social Science (SPSS Inc, version 20.0 for Windows, Chicago, IL).
Results
The data set comprised of 1095 ESUS patients with a median age of 68 years (interquartile range, 54-77 years). The baseline characteristics of the patients are presented in the Table. The median National Institutes of Health Stroke Scale score was 5 (interquartile range, 2-10), 449 patients (41.0%) were women, and 131 (12.0%) had a previous stroke or TIA. The frequency distribution of the CHADS 2 and CHA 2 DS 2 -VASc scores is presented in Figure 1 . There were 313 patients with CHADS 2 score 0 (116 women and 197 men); of which, 151 (48.2%; all men) had CHA 2 DS 2 -VASc score 0, 137 (43.8%) Figure 1 . Frequency distribution and annualized event rates for ischemic stroke/transient ischemic attack (TIA) recurrence and mortality for congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or TIA (CHADS 2 ; top) and congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category (CHA 2 DS 2 -VASc; bottom) scores' strata. 
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had CHA 2 DS 2 -VASc score 1 (96 women and 41 men), and 25 (8%) had CHA 2 DS 2 -VASc score >1 (20 women and 5 men).
Event Rates During Follow-Up
The median follow-up was 31 (interquartile range, 14-59) months corresponding to 3285 patient-years. There were totally 159 ischemic stroke/TIA recurrences (14.5%) and 148 deaths (13.5%), which correspond to 4.8 stroke recurrences and 4.5 deaths per 100 patient-years. The annualized event rates for ischemic stroke/TIA recurrence and mortality across the CHADS 2 and CHA 2 DS 2 -VASc scores are presented in Figure 1 . There were 24 (2.2% per year) ischemic stroke/TIA recurrences (7 women and 17 men) and 12 (1.1% per year) deaths (4 women and 8 men) in patients with CHADS 2 score 0 (followed-up for a median of 41.3 months); among them, there were 10 ischemic stroke/TIA recurrences and 2 deaths in 151 patients with CHA 2 DS 2 -VASc score 0 (all men), 10 ischemic stroke/TIA recurrences and 8 deaths in 137 patients with CHA 2 DS 2 -VASc score 1 (5 and 3 in women and 5 and 5 in men), and 4 ischemic stroke/TIA recurrences and 2 deaths in 25 patients with CHA 2 DS 2 -VASc score >1 (2 and 1 in women and 2 and 1 in men).
In the low-risk CHA 2 DS 2 -VASc group (followed-up for a median of 41.0 months), there were 15 (1.7% per year) ischemic stroke/TIA recurrences and 5 (0.6% per year) deaths. The corresponding numbers were 18 (3.6% per year) and 12 (2.4% per year) in the intermediate-risk group (followed-up for a median of 36.9 months) and 126 (6.5% per year) and Cox regression analyses of the association between the prestroke congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or transient ischemic attack (TIA; CHADS 2 ) and congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category (CHA 2 DS 2 -VASc) scores and ischemic stroke/TIA recurrence (top) and mortality (bottom). Associations are presented as hazard ratios and 95% confidence intervals. Comparisons are made to patients with CHADS 2 score 0 (*), CHA 2 DS 2 -VASc score 0 (**), or low-risk CHA 2 DS 2 -VASc score (***).
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September 2016 Figure 2 ). In Kaplan-Meier analysis, compared with patients with CHADS 2 score 0, the cumulative probability of ischemic stroke/TIA recurrence was higher in patients with CHADS 2 score 1 and CHADS 2 score >1 (7.7%, 15.1%, and 18.6%, respectively; Log-rank test, P<0.001; χ 2 , 22.58; Figure 3 ). Results were similar when patients were categorized into 2 CHADS 2 groups, that is, ≤1 and >1 (Figures 2 and 3) .
In the multivariate Cox regression analysis, CHA 2 DS 2 -VASc score was independently associated with the risk of ischemic stroke/TIA recurrence: compared with low-risk CHA 2 DS 2 -VASc score, patients with intermediate-risk CHA 2 DS 2 -VASc score had a strong trend of higher risk of ischemic stroke/TIA recurrence (HR, 1.95; 95% CI, 0.98-3.90; P=0.058), whereas patients with high-risk CHA 2 DS 2 -VASc score had a significantly higher risk (HR, 3.35; 95% CI, 1.94-5.80; P=0.001; Figure 2 ). In Kaplan-Meier analysis, compared with patients with low-risk CHA 2 DS 2 -VASc score, the cumulative probability of ischemic stroke/TIA recurrence was higher in patients with intermediate-and high-risk CHA 2 DS 2 -VASc scores (6.0%, 11.0%, and 18.4% respectively; Log-rank test, P<0.001; χ 2 , 27.2; Figure 4 ). Results were similar when comparisons were made between CHA 2 DS 2 -VASc score ≤1 and CHA 2 DS 2 -VASc score >1 and between CHA 2 DS 2 -VASc score 0, CHA 2 DS 2 -VASc score 1, and CHA 2 DS 2 -VASc score >1 (Figures 2 and 4) .
In multivariate Cox regression analyses including CHADS 2 's variables only, age ≥75 years (HR, 1.47; 95% CI, 1.06-2.06; P<0.05) and history of stroke/TIA (HR, 2.86; 95% CI, 2.00-4.10; P≤0.001) only were associated with stroke recurrence. In a similar analysis for the CHA 2 DS 2 -VASc score, age ≥75 years (HR, 1.89; 95% CI, 1.23-2.90; P≤0.01) Figure 3 . Cumulative probability of recurrent ischemic stroke/transient ischemic attack (TIA) and mortality in Embolic Stroke of Undetermined Source patients according to the prestroke congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or TIA (CHADS 2 ). Left, top, Cumulative probability of ischemic stroke/TIA recurrence in patients with CHADS 2 scores 0, 1, and >1. Right, top, Cumulative probability of ischemic stroke/TIA recurrence in patients with CHADS 2 scores 0 to 1 and >1. Left, bottom, Cumulative probability of mortality in patients with CHADS2 scores 0, 1, and >1. Right, top, Cumulative probability of mortality in patients with CHADS 2 Figure 2 ). In Kaplan-Meier analysis, compared with patients with CHADS 2 score 0, the cumulative probability of death was higher in patients with CHADS 2 score 1 and CHADS 2 score >1 (3.8%, 12.1%, and 20.7%, respectively; Log-rank test, P<0.001; χ 2 , 55.25; Figure 3 ). Results were similar when patients were categorized into 2 CHADS 2 groups, that is, ≤1 and >1 (Figures 2 and 3) .
In Figure 2 ). In Kaplan-Meier analysis, compared with patients with low-risk CHA 2 DS 2 -VASc score, the cumulative probability of death was higher in patients with intermediate-and high-risk CHA 2 DS 2 -VASc score (2.0%, 7.4%, and 19.2%, respectively; Log-rank test, P<0.001; χ 2 , 57.1; Figure 5 ). Results were similar when comparisons were made between CHA 2 DS 2 -VASc score ≤1 and CHA 2 DS 2 -VASc score >1 and between CHA 2 DS 2 -VASc score 0, CHA 2 DS 2 -VASc score 1, and CHA 2 DS 2 -VASc score >1 (Figures 2 and 5) .
In multivariate Cox regression analyses including CHADS 2 's variables only, all variables but history of stroke/ TIA were associated with mortality, with age and heart failure having the largest effect. In a similar analysis for the CHA 2 DS 2 -VASc score, all variables but hypertension, history of stroke/TIA/thromboembolism, and female sex were significantly associated with mortality.
Discussion
The present study shows that the CHADS 2 and CHA 2 DS 2 -VASc scores are independently associated with the risk of ischemic stroke/TIA recurrence and death in ESUS patients. The risk of stroke recurrence and death in patients with a CHA 2 DS 2 -VASc score ≥2 is much higher compared with that in patients with a score of 0, approximately 3-fold and 15-fold, respectively.
Several guidelines recommend the use of the CHA 2 DS 2 -VASc score for treatment decisions on antithrombotic treatment in patients with AF. 14, 15 In particular, for low-risk patients with a CHA 2 DS 2 -VASc score of 0 in men or 1 in women, oral anticoagulation is not recommended; for male patients with a CHA 2 DS 2 -VASc score of 1, oral anticoagulation should be considered, whereas for patients with a CHA 2 DS 2 -VASc score of ≥2, oral anticoagulation is recommended. 11 Currently, the ideal antithrombotic treatment in ESUS patients is not clear: Figure 4 . Cumulative probability of recurrent ischemic stroke/ transient ischemic attack (TIA) in Embolic Stroke of Undetermined Source patients according to the prestroke congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category (CHA 2 DS 2 -VASc) score. Top, Cumulative probability of ischemic stroke/TIA recurrence in low-, intermediate-, and high-risk patients according to the prestroke CHA 2 DS 2 -VASc score as this is described in the Methods section. Middle, Cumulative probability of ischemic stroke/TIA recurrence in patients with CHA 2 DS 2 -VASc scores 0, 1, and >1. Bottom, Cumulative probability of ischemic stroke/TIA recurrence in patients with CHA 2 DS 2 -VASc scores 0 to 1 and >1.
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although there are no official recommendations for this specific population yet as the term ESUS was only recently introduced, the guidelines imply that antiplatelet treatment should be chosen (given that by definition cardioembolism is not confirmed ESUS). 1 However, there is accumulating evidence that perhaps oral anticoagulation may be a better choice. 1, 3 The results of the current analysis generate the hypothesis that perhaps the 2 scores may be useful in aiding treatment decisions about antithrombotic treatment in ESUS patients, which obviously needs to be investigated in future studies.
The 3 ongoing trials of anticoagulants versus aspirin will provide further insight into this issue. The RE-
5-7
The cause of ESUS is heterogeneous and may include many different entities like congestive heart failure, heart valvular pathologies, nonstenotic atherosclerotic lesions, and others. In this context, we hypothesized that risk stratification for stroke recurrence and mortality in ESUS patients would require a tool that includes several parameters (eg, congestive heart failure, proatherogenic pathologies, such as diabetes mellitus, and others) associated with the possible underlying ESUS causes. As such, the CHADS 2 and CHA 2 DS 2 -VASc scores were 2 excellent candidates given the covariates that they include, which are closely associated with many of the potential underlying ESUS causes. Obviously, the conclusions of the present study are likely because of the shared risk factors, as is the case also in other non-AF entities. 12, 16 The main strengths of this analysis are the large size of the study population involving >1000 consecutive ESUS patients from 11 stroke registries from 7 countries in Europe and America, the long follow-up of approximately 3 years, and the standardized definition of ESUS based on the criteria proposed by the Cryptogenic Stroke/ESUS International Working Group. 1 As far as we are aware, this is the largest data set focused on using risk scores to predict stroke recurrence and mortality. In addition, we performed several analyses using different categorizations of the CHADS 2 and CHA 2 DS 2 -VASc scores, which yielded similar results, thus strengthening our conclusion that these 2 scores are independently associated with the risk of ischemic stroke/TIA and death in ESUS patients. On the other hand, it is characterized by the inherent limitations of any retrospective multicenter analysis of prospectively collected multicenter data, such as collection and registration bias, as well as unregistered confounding factors.
In conclusion, the CHADS 2 and CHA 2 DS 2 -VASc scores are independently associated with the risk of ischemic stroke/ TIA and death in ESUS patients. The risk of ischemic stroke/ TIA recurrence and death in patients with a CHA 2 DS 2 -VASc Figure 5 . Cumulative probability of death in Embolic Stroke of Undetermined Source patients according to the prestroke congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category (CHA 2 DS 2 -VASc) score. Top, Cumulative probability of mortality in low-, intermediate-, and high-risk patients according to the prestroke CHA 2 DS 2 -VASc score as this is described in the Methods section. Middle, Cumulative probability of mortality in patients with CHA 2 DS 2 -VASc scores 0, 1, and >1. Bottom, Cumulative probability of mortality in patients with CHA 2 DS 2 -VASc scores 0 to 1 and >1. 
